Study wrapper · #619
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
Editor's note
This clinical-pharmacology review surveys GABA-related sedative-hypnotics and their abuse potential, and pointedly notes that Selank (along with phenibut) is a 'poorly studied Russian drug' sold to US consumers as a dietary supplement. For AllAboutAminos this is valuable regulatory and market context: it frames Selank as under-characterized and its supplement-channel availability as a concern, rather than as a validated therapeutic. The review is not primary evidence and does not present new Selank data; its treatment of Selank is brief and cautionary. It is worth surfacing precisely for its skeptical, consumer-safety framing. The broader claims discipline applies: nothing here supports efficacy or safety assertions for Selank in humans.
Plain-language abstract
This review article discusses a range of sedative and calming drugs that work through the brain's GABA system, including their medical uses and their potential for misuse. It notes that Selank, a peptide developed in Russia, is not well studied and is nonetheless sold to US consumers as a dietary supplement, which the authors flag as a concern. The article's value here is context: it presents Selank as under-researched and cautions about products marketed with little safety data. It does not report new experiments on Selank or establish its safety or benefit. This is a review offering a cautious, consumer-protection perspective rather than direct evidence about what Selank does.